Guggenheim Raises Damora Price Target to $60 on Bigger Myelofibrosis Outlook
Guggenheim named Damora a Best Idea, citing the potential for earlier, longer mCALR treatment to expand the myelofibrosis and essential thrombocythemia markets.
/ 185 items
#XY Analyst Up/Down↓
B. Riley Initiates Precigen at Buy as Papzimeos Launch Gains Steam
B. Riley rates Precigen Buy on Papzimeos, the first FDA-approved adult RRP therapy, plus Q2 profit and management’s year-end cash break-even goal.
Seaport Gets Strong Buy as GlyphAllo Data Looms in 2027
The Glyph pipeline, 2027 catalyst, and cash runway into 2029 drive the case.
Goldman Sachs Starts Sagimet at Sell, Sees 35% Downside Into AURORA
The bank says AURORA endpoints and teen compliance may not match China’s Phase 3 results.
Nektar Shares Slide as Jury Weighs Lilly Lawsuit Over Rezpeg
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
Guggenheim Upgrades Editas Medicine to Buy on EDIT-401 Cholesterol Therapy
Guggenheim raised Editas Medicine to Buy with a $5 target, citing EDIT-401’s potential in high-LDL ASCVD patients as its first human trial nears.